Pizzie Nick sold $7.9M of AXSM
Pizzie Nick (Chief Financial Officer) sold 33,000 shares of Axsome Therapeutics, Inc. (AXSM) at $240.09 ($7.92M total) on 2026-06-09 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The key new information is the same-day open-market sale by the CFO and the stated use of a pre-arranged 10b5-1 plan; no other company fundamentals are updated in the text.
Market read
Traders may treat this as a small sentiment datapoint rather than a fundamental catalyst, given the 10b5-1 structure.
What to watch
Insider sales can still affect short-term sentiment/flow, especially if the market interprets the size ($7.9M) as notable—even when 10b5-1 is present.
Background
The article is a primary-source SEC Form 4 insider transaction disclosure for Axsome Therapeutics.
Ticker impact
Axsome Therapeutics CFO Pizzie Nick sold 33,000 shares in an open-market transaction worth about $7.9M, per a fresh SEC Form 4 filed today.
Low near-term impact; any reaction is more likely sentiment/positioning than new company fundamentals.
The disclosure is a Form 4 insider sale (not a buy), but it explicitly states a pre-arranged 10b5-1 plan, which typically reduces interpretive weight versus discretionary selling.
Market effects
Minimal read-through to the biotech sector; this is company-specific insider transaction data without clinical/regulatory updates.
None indicated; US-listed issuer filing only.
None indicated; no cross-border deal/regulatory action mentioned.
Counterpoint
Because the sale is under a pre-arranged 10b5-1 plan, it may reflect scheduled liquidity rather than bearish expectations, so traders may ignore it unless paired with other negative catalysts.
Key entities
- issuerAxsome Therapeutics, Inc.
US biotech issuer whose CFO filed an SEC Form 4 for an open-market sale.
- insiderPizzie Nick
Chief Financial Officer who sold 33,000 shares under a pre-arranged 10b5-1 plan.
